QIAGEN powered by

Webinars and events

« All Events

  • This event has passed.

How clinical labs can confidently assess cancer-associated variants with real-world data and expert-curated genomic evidence

November 16, 2023 @ 1:00 pm - 2:00 pm

Across various stages of the clinical oncology workflow, from panel design to genomic testing and molecular tumor boards, the identification and validation of actionable genomic alterations is critical. The advent of next-generation sequencing (NGS) has led to an exponential increase in the number of variants detected in tumor testing, posing a challenge for clinical cancer genetics professionals seeking to confidently discern clinically relevant mutations that can guide patient care decisions.
Join Dr. Umadevi Thirumurthi, Associate Director of Global Product Management for Oncology at QIAGEN Digital Insights as she discusses how the Human Somatic Mutation Database (HSMD), an expert-curated somatic variant database, can enhance your clinical NGS workflow.
Attendees will learn how HSMD:
  • Can be used to design targeted panels, streamline somatic variant analysis, and support molecular tumor board decisions;
  • Provides access to data from over 419,00 real-world oncology cases and human-certified expert curation
  • Enables users to effortlessly explore mutational characteristics across genes, synthesize critical information from drug labels and professional guidelines, investigate ongoing clinical trials, and access comprehensive annotations for each observed variant
Register for event

Details

Date: November 16, 2023
Time:
 1:00 pm - 2:00 pm
Register for event

Venue:

Virtual – Americas – EST
United States
View Venue Website
Event Categories:
,
Event Tags:

Venue

Virtual – Americas – EST
United States

Other

Category
Clinical, Webinar

Related Events

Register for event

On-demand Webinars


  • Supercharge your AI in drug discovery with high-quality biomedical data

    If you’re working in pharma or biotech, you likely rely on artificial intelligence (AI) to help you identify new drug targets or plausible biomarkers for disease within large data sets. Yet AI alone isn’t enough. A large proportion of Biomedical data have errors and are unstructured. For AI models to provide reliable insights, the underlying data must be of ‘hig...

    WATCH NOW
  • Scale up NGS bioinformatics analysis throughput with QIAGEN CLC Genomics cloud computing

    Scale your NGS analysis to match your sequencing throughput using our QIAGEN CLC Genomics cloud solution. In this webinar, you’ll learn about the flexible and powerful setup for running your NGS sequence analyses on Amazon Web Services (AWS). You’ll learn how to use QIAGEN CLC Genomics Workbench to customize workflows and send analyses to AWS Batch for execution. ...

    WATCH NOW
  • QIAGEN Biomedical Knowledge Base: Data- and analytics-driven drug discovery

    Biomedical relationships knowledge is now required for innovative data- and analytics-driven drug discovery. It powers biomedical knowledge graph analysis, artificial intelligence (AI)-driven target identification and many more applications. In this one-hour training, you’ll get an introduction to QIAGEN Biomedical Knowledge Base. You’ll learn how to tackle appli...

    WATCH NOW
  • Part 1: AI-Powered Hereditary Disease Diagnostics: Closing the Gap in Clinical Exome Completeness

    Clinical exome sequencing (CES) is increasingly being adopted by small and mid-sized laboratories to diagnose genetic diseases, aid treatment decisions, and provide prognostic information. However, the exponential increase in genetic data generated from exome and genome panels poses significant workflow challenges. The ability to prioritize potentially pathogenic vari...

    WATCH NOW
  • A breakthrough for rare disease: Completing the Clinical exome gap!

    In its latest release, QCI Interpret for Hereditary extends its market-leading content with further advancements in Artificial Intelligence (AI) for enhanced capabilities in clinical exome NGS testing. Now, with the addition of AI-derived literature references for rare disease genes, QCI Interpret provides complete exome coverage, on top of the existing unrivalled man...

    WATCH NOW
  • What’s new in QIAGEN IPA Fall Release 2023?

    Interested in learning about new features and functionalities that have been added to IPA lately? During this webinar, we will highlight the updates from the QIAGEN IPA Fall Release and from previous releases from this year. Topics, amongst others, will be • Newly added findings and pathways • Reactome pathways • Artificial intelligence approves to pathways ...

    WATCH NOW
Sample to Insight